g10r
Joined 12 years ago
Joined 12 years ago
Chamath is currently leading four biotech SPACS: DNAA, DNAB, DNAC and DNAD, each with a stated target, neurology, oncology, organs & immunology. Anyone looking to invest in the SPAC today should consider the likelihood of this happening, the potential targets, and the sponsors history.
Or you can wait for an announcement around a proposed merger, even up to the day the official stock starts being traded.
Again, just depends on risk tolerance. It's nice to least have the option to take part in these deals.
Said another way, 'anyone' can invest 'any' amount in a public stock today and lose it all tomorrow. Heck people were even suckered into mortgages they couldn't afford by our trusty banks.
Apple/Nike/Target, sure. Tesla, no.
“Every person in your company is a vector. Your progress is determined by the sum of all vectors.” — Elon Musk
Twitter: @grahamgarner Email: grahamgarner1 [at] gmail